IPO ChampIPO Insights
IPO Champ LogoIPO Champ Logo

IPOs

IPO Calendar
GMP Tracker
Subscription Status
Allotment Status
Stock Broker
  • Follow us on Instagram
  • Follow us on Facebook
  • Follow us on Threads
  • Follow us on YouTube
  • Follow us on Telegram
  • Follow us on WhatsApp
HomeIPOCorona Remedies

About Corona Remedies

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.Presently, the company owns two manufacturing facilities located in the states of Gujarat.As of December 31, 2024, the company had 88 R&D employees.

Checklist Quality Analysis

Revenue Growth

Live IPOs

National Stock Exchange of India logo

National Stock Exchange of India

Mainboard
Open  Close17th Sep 2026 - 21st Sep 2026
Issue Size22561.57 Cr
Min. Qty8 Shares
Issue Price₹ 1700.00
Live IPO
Antala Industries logo

Antala Industries

SME
Open  Close29th Oct 2026 - 5th Nov 2026
Issue Size22.98 Cr
Min. Qty2000 Shares
Issue Price₹ 62.00
Live IPO
Companies NameOpen - CloseIssue SizeMin. QtyIssue PriceApply
National Stock Exchange of India logo

National Stock Exchange of India

Mainboard
17th Sep 2026 - 21st Sep 202622561.57 Cr8 Shares₹ 1700.00
Antala Industries logo

Antala Industries

SME
29th Oct 2026 - 5th Nov 202622.98 Cr2000 Shares₹ 62.00
See All Live IPOs
IPO Champ LogoIPO Champ Logo

IPO Champ helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO CalendarGMP TrackerSubscription StatusAllotment Status

IPOs

All IPOsLive IPOsUpcoming IPOsClosed IPOsListed IPOs

Resources

NewseBooks

Company

HomeAbout UsPrivacy PolicyTerms of Service

About IPO Champ

IPO Champ is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@ipochamp.com.

Please read all offer documents and risk disclosures carefully before investing. IPO Champ does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Champ. All rights reserved.

Want to stay updated?Subscribe to our newsletter

Corona Remedies

Corona Remedies

Open Date

08 Dec 2025

Close Date

10 Dec 2025

listed

Min Investment

₹14868

Lot Size

14 Shares

Issue Size

₹655.37 Cr

Price Range

₹1008 - ₹1062

Listing Date

Dec 15, 2025

IPO Doc

RHP PDF

Company Valuation

Earning Expansion

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

₹302.5(+28.00%)GMP
28.48%Prediction Listing Gain

Grey Market Premium (GMP) Trend

Corona Remedies IPO - Issue Objectives

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders. The company want to achieve the benefits of listing its shares on the stock exchanges.

1

Carry out the offer for sale

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders.

2

Listing on stock exchanges

The company want to achieve the benefits of listing its shares on the stock exchanges.

IPO Subscription Status

QIB
293.80x
NII
220.18x
Individual
30.29x
Total
144.49x

Times subscribed by category (bars capped at 10x for readability). Dashed line marks 1.0x (fully subscribed).

Financials of Corona Remedies

In Cr.

Key Performance Indicator30-Jun-25 (In Cr.)31-Mar-25 (In Cr.)31-Mar-24 (In Cr.)31-Mar-23 (In Cr.)
Revenue348.561202.351020.93891.10
EBITDA71.80245.91161.19135.03
Expenses
Profit After Tax46.20149.4390.5084.93
Assets1012.38929.86830.58595.02
Net Worth607.02606.34480.41408.52
Reserves545.86545.18419.25347.36
Borrowing106.6562.70134.142.33

Corona Remedies - Promoter(s)

Dr. Kirtikumar Laxmidas Mehta

Niravkumar Kirtikumar Mehta

Ankur Kirtikumar Mehta

Pre Issue Share Holding

72.50%

Post Issue Share Holding

N/A

About Strength & Risks

Why this IPO looks interesting

Key positives investors may want to consider before applying.

01

Strong portfolio in fast-growing therapeutic areas

The firm has a deep anchor in the fast-growing categories in India: women's healthcare, cardio-diabeto, pain management, and urology. These four areas together contributed 68.26% of domestic sales, growing at a 22.40% CAGR from MAT June 2022-2025. This strategic alignment to long-term demand provides volume stability and visibility for the portfolio.

02

Leadership across flagship “engine brands”

The firm has 27 “engine brands” that alone contributed 72.34% of domestic sales in MAT June 2025. Key brands like COR, Trazer, Cor-9, B-29, Myoril and Tricium dominate their respective sub-categories, with 12 of these brands ranked within the top 5 in their therapeutic segments.

03

Limited exposure to NLEM list

The company’s portfolio has limited exposure to the National List of Essential Medicines. Only 9.76% of its sales fall under NLEM, which is the 7th lowest amongst the top 30 pharmaceutical companies in IPM, versus 17.51% for the overall pharma market, giving it far better room to protect margins and avoid regulatory price compression.

What investors should watch closely

Risk factors and possible pressure points around the offer.

01

Geographical concentration

96.33% of revenues are generated domestically in FY25. Approximately 47.30% of domestic sales in MAT June 2025 come from only five western states: Gujarat, Maharashtra, Goa, Chhattisgarh, and MP. Thus, any slowdown in those markets, changes in regulations, or even issues with distributors disproportionately hurt growth.

02

Raw material and API supply uncertainty

The company does not have long-term contracts with most of its suppliers and has high dependence on third parties for APIs as well as finished goods. Total purchases represented 27.96% of expenses in FY25. Prices are volatile, with suppliers potentially giving higher priority to competitors. There’s also additional dependence on the related-party API supplier, La Chandra Pharmalab.

Contact Details

Corona Remedies

CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059

+917940233000
complianceofficer@coronaremedies.com
https://www.coronaremedies.com/

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200
ipo@bigshareonline.com
https://ipo.bigshareonline.com/ipo_status.html

Corona Remedies IPO - FAQs

Corona Remedies IPO is a Mainboard IPO. The issue is priced at ₹1008-1062 per equity share. The minimum order quantity is 14 Shares. The IPO opens on 8 Dec, and closes on 10 Dec. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

IPO Timeline

  • Pre Apply2025-12-04
  • Bidding Starts2025-12-08
  • Bidding Ends2025-12-10
  • Allotment Finalisation2025-12-11
  • Release of Funds2025-12-12
  • Demat Transfer2025-12-12
  • Listing2025-12-15
04

Growing focus on chronic & sub-chronic therapies

The company has been shifting focus towards categories with longer prescription duration, better patient stickiness, and more profitability. 70.10% of its domestic sales came from chronic/sub-chronic products in MAT June 2025, versus 63.82% in June 2022. This helps ensure recurring revenue and predictable cash flows.

05

Strong sales infrastructure and deep engagement

The company has built a pan-India commercial engine reaching specialists and super-specialists. ~75.75% of its prescriptions come from specialists vs 60.96% for the broader market, and more than 75% of sales come from urban/semi-urban markets, where purchasing power and compliance are higher.

03

Trademark protection gaps

Although there are 194 registered trademarks, 67 were opposed / objected / refused / abandoned, and another 29 applications are pending. Some of the engine brands, like Cortel, Argihope, and Dosin, do not have final registrations. In case of similar brand name usage by competitors or any disputes arising, the company could lose brand recognition and revenue.

04

Heavy dependence on a few therapeutic categories

The company’s product portfolio is concentrated in a limited number of therapeutic categories, such as women's healthcare, cardio-diabeto and pain management therapies. In FY25, these 3 together accounted for 62.40% of total revenue. Any shift in physician prescriptions toward competing alternatives or the launch of viable new alternatives may bring down sales and margins for the company.

05

Regulatory approvals still pending for the Solan facility

This plant at Solan is one of the major production hubs for the company, but a lot of significant operational approvals are still pending. These include approval for NOC for the extraction of groundwater, authorisation of bio-medical waste, and fire safety NOC. Failure or delay in any of these could lead to forced shutdowns, penalties, or disruptions in production for the company.